Targeted Diagnostics
Early detection and monitoring of neurodegenerative and neurodevelopmental disorders, healthy aging
Targeted approach: brain-enriched microRNA biomarkers in plasma
Collaborations with academia, medical centers, disease foundations and industry
Peer-reviewed publications, grant awards, patents
Technology
At DiamiR, we focus on the development and commercialization of an innovative technology based on analysis of brain-enriched microRNA biomarkers in blood plasma to be used for screening, early and differential diagnosis, enrollment of better defined participants into clinical trials, as well as disease progression and treatment monitoring.
Leadership
Alidad Mireskandari, PhD, MBA
Chief Executive Officer
Gyanendra Kumar, PhD
VP, Assay Development
Kenny K. Ablordeppey, MS
Laboratory Supervisor & Project Manager
Gary Anthony
Chief Financial Officer
Advisory Board
Henry (Harv) M. Rinder, MD, MA, FACP, FASCP
Professor of Laboratory Medicine & Internal Medicine (Hematology)
Yale School of Medicine & Yale-New Haven Hospital
Robert Rissman, PhD
W.M. Keck Endowed Chair in Medicine and Professor Physiology and Neuroscience at the University of Southern California (USC).
Founding Director of the Neuroscience Translational Research Division (NTRD) at USC Alzheimer’s Therapeutic Research Institute (ATRI)
Biomarker Unit Lead for the Alzheimer’s Clinical Trials Consortium (ACTC) and USC’s Alzheimer’s Disease Research Center.
Mikhail Denissenko, MD, PhD
Advisor
